Core Viewpoint - The company has submitted a CE certification application for its transcatheter mitral valve repair system, JensClip, marking a significant step in its internationalization strategy [1][2] Group 1: Product Development - JensClip is designed for the treatment of severe mitral regurgitation, featuring a user-friendly and reliable operation [1] - The device incorporates a claw-wedge mechanical locking design that allows for locking at any angle, ensuring stable and reliable coaptation of the leaflets [1] - The diamond-shaped valve clip design facilitates retrieval and repositioning, enhancing safety during the procedure [1] - The integrated detachment design aims to reduce potential operational risks during the detachment process, effectively shortening the operational time [1] Group 2: Clinical and Regulatory Progress - The one-year clinical follow-up results and challenging case applications of JensClip have been presented at major international academic conferences, demonstrating excellent safety and efficacy indicators [1] - The product has completed the registration application submission to the National Medical Products Administration in China and is currently under review [2] - JensClip has successfully commenced clinical applications overseas, with the company actively promoting the registration process to meet broad clinical needs [2]

Core Insights - The investment landscape in the innovative pharmaceutical sector has significantly improved in 2025, with a notable resurgence in market activity and valuations, particularly in Hong Kong's stock market, where the biotech index surged over 100% [1][7] - The strategic decision by Qiming Venture Partners to continue investing in innovative drugs and medical devices during a downturn has proven to be a successful move, leading to substantial returns and a growing portfolio of successful investments [1][6] Investment Activity - Qiming Venture Partners invested in over 30 projects in the medical innovation sector in 2025, with total investments exceeding 30 billion yuan, including decisions made in the latter half of 2024 [2][6] - Notable investments include Cornerstone Robotics, a Hong Kong-based surgical robot company, which has raised over 30 billion yuan and is positioned to compete with imported brands [2][3] Market Trends - The IPO landscape for biotech companies has become increasingly vibrant, with nearly 10 companies submitting applications in November alone, and the number of successful biotech IPOs in Hong Kong doubling compared to the previous year [7][8] - International investors are shifting their focus back to Chinese innovative drug companies, recognizing their clinical data and potential for collaboration with global pharmaceutical leaders [7][9] Future Outlook - The global influence of Chinese medical innovation is on the rise, with projections indicating that approximately 40% of new drug projects licensed in by major global pharmaceutical companies will come from Chinese biotech firms by 2025 [9][10] - Qiming Venture Partners is committed to supporting the globalization of Chinese pharmaceutical companies, facilitating partnerships with international firms and helping navigate global regulatory environments [10]

Core Viewpoint - The investment strategy for the medical device sector in 2026 will focus on overseas expansion and innovation, with an emphasis on companies that demonstrate strong certainty in market growth and product development [1] Group 1: Investment Focus - The strategy highlights three categories of companies to watch: 1. Leaders in digestive endoscopy consumables that are expanding into mature overseas markets and are less affected by domestic price pressures [1] 2. Domestic brands with strong market presence in wearable innovative products and accelerated overseas market expansion in home medical devices [1] 3. Hong Kong-listed medical device companies that are innovating with differentiated products in the cardiovascular intervention field [1]

Core Viewpoint - The investment strategy for the medical device sector in 2026 will focus on overseas expansion and innovation, emphasizing companies with strong product innovation capabilities and those that have mitigated domestic market price pressures [1] Group 1: Investment Focus Areas - Emphasis on leading companies in the digestive endoscope consumables sector that are expanding into mature overseas markets and are beginning to see the bottoming out of domestic procurement impacts [1] - Attention to home medical device leaders with strong domestic brand power and innovative wearable products that are accelerating their expansion into overseas markets [1] - Focus on Hong Kong-listed medical device companies that are innovating with differentiated products in the cardiovascular intervention field [1]

"创新医疗器械特别审查程序"是国家药监局为鼓励医疗器械创新设立的优先审评程序，聚焦技术领先性，助力高端医疗器械国产化。进入该"绿色通道"，意 味着ReachTact®经导管主动脉瓣置换手术辅助系统的技术领先性和显著的临床应用价值获得了国家监管机构的认可。此举将为该系统后续的注册审批提供前 置指导和优先办理，极大缩短其从实验室走向市场的时间。（王晓辉） ReachTact®经导管主动脉瓣置换手术辅助系统 智程医疗针对上述临床问题，自主研发了ReachTact®"经导管主动脉瓣置换手术辅助系统"。相比传统术式，这一平台具备多项显著优势：产品采用主从式控 制系统，术者可以在射线屏蔽环境下安全完成TAVR手术；机械臂稳定抓持超硬导丝及介入器械，可实现亚毫米级精准操控；与传统手术推拉旋转完全相同 的操作设计，叠加低延时触觉力反馈功能，缩短年轻术者学习曲线并保证患者安全；单人对导丝及输送器的同步操控，降低手术团队人数及配合要求；操作 手柄采用自然交互式设计，高度仿生，还原传统TAVR手术中术者对输送器、球囊、导丝推送，及瓣膜释放回收旋转的操作。未来，该系统还可以结合5G等 新技术可实现远程手术，助力优质医疗资源下沉，打破 ...

Core Viewpoint - The article discusses the recent approval of innovative medical devices by the National Medical Products Administration (NMPA) in China, highlighting the advancements in the field of interventional cardiology and urology [2][3]. Group 1: TaurusTrio Transcatheter Aortic Valve System - The TaurusTrio system, developed by Peijia Medical Technology (Suzhou) Co., Ltd., addresses the challenges of aortic regurgitation (AR) in transcatheter aortic valve replacement (TAVR) procedures, particularly the difficulties in anchoring due to minimal calcification [7][12]. - The system features an integrated positioning key that allows for stable contact with the native valve leaflets, providing a structural solution to the anchoring issue faced by AR patients [12]. - TaurusTrio enhances operational controllability with adjustable bending and rotational capabilities, which significantly reduces the risk of complications and improves release accuracy during procedures [13]. - The design includes a large mesh outlet that preserves future coronary access for patients, reflecting a growing trend in clinical evaluations of TAVR systems [14]. - Peijia Medical, established in 2012, has positioned itself as a key player in the domestic structural heart disease intervention market, with the approval of TaurusTrio expanding its product offerings from stenosis to regurgitation treatments [16]. Group 2: Disposable Sterile Urinary Catheter - The disposable sterile urinary catheter, developed by Taizhou Dubomai Medical Devices Co., Ltd., includes single, double, and triple lumen models tailored for various clinical scenarios, with a core innovation being a polylysine coating that inhibits bacterial growth [18]. - This coating mechanism reduces bacterial adhesion and biofilm formation, representing a significant advancement over traditional sterile catheters that rely solely on standard sterilization methods [18]. - Taizhou Dubomai focuses on innovation in urinary and urological devices, and the approval of this catheter signifies a breakthrough in medical consumables, showcasing a shift towards functional improvements in domestic products [19].

格隆汇12月7日丨沛嘉医疗-B(09996.HK)公告，于近日，公司收到中华人民共和国国家药品监督管理局 ("国家药监局")的受理通知书，确认受理TaurusNXT"非醛交联"干瓣经导管主动脉瓣置换("TAVR")系统 ("系统")的注册申请。 TaurusNXT为公司内部研发的第三代TAVR系统，采用已获得专利的非醛生物组织交联技术，消除了瓣 膜钙化的根本原因，而瓣膜钙化是人工瓣膜退化的主因。该技术旨在提升人工主动脉瓣("人工主动脉 瓣")的耐用性及生物相容性。此外，与使用甘油的传统干燥组织技术相比，该系统采用超低温真空冷冻 干燥技术。此方法帮助保持瓣膜组织的物理完整性，同时亦可将人工主动脉瓣预装到输送器("输送器") 上。TaurusNXT的输送器亦进行了升级，使其具备可回收及可调弯的特性，有助于医生更加容易将人工 主动脉瓣引导至目标植入位置，从而进一步提高手术的安全性。 该系统已获国家药监局创新医疗器械特别审批程序受理，后续将优先评估及审批。 ...

该系统已获国家药监局创新医疗器械特别审批程序受理，后续将优先评估及审批。 智通财经APP讯，沛嘉医疗-B(09996)发布公告，于近日，公司收到中华人民共和国国家药品监督管理局 的受理通知书，确认受理TaurusNXT® "非醛交联"干瓣经导管主动脉瓣置换("TAVR")系统的注册申请。 TaurusNXT®为公司内部研发的第三代TAVR系统，采用已获得专利的非醛生物组织交联技术，消除了 瓣膜钙化的根本原因，而瓣膜钙化是人工瓣膜退化的主因。该技术旨在提升人工主动脉瓣的耐用性及生 物相容性。此外，与使用甘油的传统乾燥组织技术相比，该系统采用超低温真空冷冻乾燥技术。此方法 帮助保持瓣膜组织的物理完整性，同时亦可将人工主动脉瓣预装到输送器上 。 TaurusNXT®的输送器 亦进行了升级，使其具备可回收及可调弯的特性，有助于医生更加容易将人工主动脉瓣引导至目标植入 位置，从而进一步提高手术的安全性。 ...

Investment Rating - The report does not explicitly state an investment rating for the industry [2] Core Views - The pharmaceutical and biotechnology sector saw a weekly increase of 2.67%, underperforming the Wind All A index (2.9%) but outperforming the CSI 300 index (1.64%). The raw material drug sector experienced a decline of 4.27%, while chemical preparations and pharmaceutical circulation products increased by 4.18% and 3.71%, respectively [3][8] - Recent policies in Shanghai and Beijing aim to support the high-quality development of the medical device industry, indicating a shift towards innovation and global competitiveness in this sector. The report suggests monitoring the transformation progress of leading companies in the medical device field [3][12] - Flu activity is on the rise, with the percentage of flu-like cases reported by sentinel hospitals in southern provinces reaching 7.8%, up from 6.8% the previous week, and higher than the same period in 2022 and 2024 [3][11] Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector increased by 2.67% from November 24 to November 28, 2025, with raw material drugs declining by 4.27% and chemical preparations increasing by 4.18% [8][9] - Individual stock performances included significant gains for Haiwang Biological (38.2%), Yue Wannianqing (36.2%), and Guangji Pharmaceutical (31.7%), while *ST Changyao (-15.3%), Huitai Medical (-9.6%), and Kangwei Century (-8.8%) saw notable declines [11] Industry News and Key Company Announcements Important Industry Events - The report highlights the increase in flu-like illness percentages in both southern (7.8%) and northern (8.6%) provinces, indicating a significant rise in flu activity compared to previous years [11][12] Industry News - Significant approvals were noted, including the NMPA's approval of Xinmeiyue® for treating moderate to severe plaque psoriasis and the FDA's accelerated approval of Sibeprenlimab for IgAN treatment [12][14] Company Announcements - Notable announcements include the FDA approval of a generic injectable drug by Jianyou Co. and the successful completion of a Phase III trial for JS001sc, a subcutaneous PD-1 monoclonal antibody for non-small cell lung cancer [15][16]

Core Insights - Recent measures have been implemented in cities like Beijing and Shanghai to support the high-quality development of the medical device industry, focusing on various aspects such as clinical research, registration, production, application, cluster development, digital empowerment, and international expansion [1] - The support policies for innovative medical devices from national and local governments are expected to strengthen, leading to an acceleration in medical device innovation [1] - The company remains optimistic about structural investment opportunities in the medical device sector by 2026, suggesting investors take advantage of performance and valuation recovery opportunities in companies expected to see growth in 2026 [1] - Long-term investment opportunities in the medical device industry are anticipated to arise from innovation, international expansion, and mergers and acquisitions, with the sector's innovation and international capabilities gaining recognition and valuation being restructured [1]